These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23937387)

  • 1. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain.
    Imanaka K; Tominaga Y; Etropolski M; van Hove I; Ohsaka M; Wanibe M; Hirose K; Matsumura T
    Curr Med Res Opin; 2013 Oct; 29(10):1399-409. PubMed ID: 23937387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
    Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
    Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
    Lange B; von Zabern D; Elling C; Dubois C
    Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
    Serrie A; Lange B; Steup A
    Curr Med Res Opin; 2017 Aug; 33(8):1423-1432. PubMed ID: 28537501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
    Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
    J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
    Coluzzi F; Ruggeri M
    Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
    Vinik AI; Shapiro DY; Rauschkolb C; Lange B; Karcher K; Pennett D; Etropolski MS
    Diabetes Care; 2014 Aug; 37(8):2302-9. PubMed ID: 24848284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
    Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
    Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials.
    Lange B; Sohns M; Tempero J; Elling C
    Curr Med Res Opin; 2018 Dec; 34(12):2113-2123. PubMed ID: 30200781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.